Chardan Capital Markets upgraded Sage Therapeutics (NASDAQ: SAGE) from Neutral to Buy with a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Upgrades

Sage Therapeutics (SAGE) PT Raised to $140 at Canaccord GenuityNovember 10, 2017 7:22 AM Sage Therapeutics (SAGE) PT Raised to $135 at CowenNovember 9, 2017 3:20 PM Sage Therapeutics (SAGE) PT Raised to $105 at StifelNovember 9, 2017 12:43 PM Sage Therapeutics (SAGE) PT Raised to $123 at Leerink PartnersNovember 9, 2017 12:13 PM Sage Therapeutics (SAGE) PT Raised to $100 at Needham & CompanyNovember 9, 2017 11:34 AM Sage Therapeutics (SAGE) PT Raised to $145 at RBC CapitalNovember 9, 2017 10:47 AM Sage Therapeutics (SAGE) Hits 'Very Significant Milestone' - BMONovember 9, 2017 10:12 AM Pre-Open Movers 11/09: (OTIC) (SAGE) (ROKU) Higher; (VSTO) (OPK) (EPC) Lower (more...)November 9, 2017 9:23 AM SAGE Therapeutics (SAGE): Primary Endpoints in Both Phase III PPD Trials Met - SuntrustNovember 9, 2017 7:17 AM Form 8-K Sage Therapeutics, Inc. For: Nov 09November 9, 2017 7:11 AM SAGE Therapeutics (SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary EndpointNovember 9, 2017 6:42 AM SAGE Therapeutics (SAGE) Says Brexanolone Achieved Primary Endpoints in Both Phase 3 Trials in Postpartum DepressionNovember 9, 2017 6:28 AM Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum DepressionNovember 9, 2017 6:00 AM